Company / Cash & Equivalents
Vaxcyte, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$174.0M
FY2025
5-year range
$69.0M / $834.7M
FY2021-FY2025
Trend
-55.2%
vs FY2024
Sector context
#99 of 207
Health Care
What the data says
At $174M, Vaxcyte, Inc.'s cash & equivalents ranks #99 of 207 in the Health Care sector. Cash & Equivalents has declined for 3 consecutive years, from $835M in FY2022 to $174M in FY2025.
Based on SEC 10-K filings.
$174M in FY2025 with a 5-year CAGR of -14.7%.
Declined from $397M to $174M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -40.7%
- 5-Year CAGR
- -14.7%
- 10-Year CAGR
- -
Sector benchmark
#99 of 207 in Health CareTop 48% of 207This company $174.0M Sector average $669.5M
▼
-74.0% below sector average
Key checks
Key Insights
- Vaxcyte, Inc.'s cash & equivalents has declined for 3 consecutive years.
- 5-year CAGR of -14.7%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 55.2% year-over-year.
- Ranks #99 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $174.0M | -55.2% |
| FY2024 | $387.9M | -2.4% |
| FY2023 | $397.5M | -52.4% |
| FY2022 | $834.7M | +1109.9% |
| FY2021 | $69.0M | -82.1% |
| FY2020 | $386.2M | +554.8% |
| FY2019 | $59.0M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026